search
Back to results

The Efficacy and Safety Study of Anti-hypertension Combination Drug in Patients Uncontrolled With Monotherapy.

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Amosartan® tab
Cozaar® plus pro tab
Sponsored by
Hanmi Pharmaceutical Company Limited
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 20 aged or over
  • Patients with blood pressure measured at Visit 1; 90mmHg≤MSDBP mmHg if on anti-hypertensive drugs, 95mmHg≤MSDBP mmHg if not on anti-hypertensive drugs
  • Patients with blood pressure measured at Visit 2 were 90mmHg≤MSDBP mmHg (non-responder to Losartan 100mg for 4-week treatment)

Exclusion Criteria:

  • Patients with too high Blood pressure

    •≥ sitSBP 20mmHg or ≥ sitDBP 10mmHg of variation in three measurements from the reference arm selected at Screening

  • History of hypersensitivity to CCB ,Angiotensin II receptor blockers or Sulfonamide.
  • Secondary hypertension or suspected to be

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    Amosartan® tab

    Cozaar® plus pro tab

    Arm Description

    Amlodipine 5mg /Losartan 100mg

    Losartan 100mg/ HCTZ 12.5mg

    Outcomes

    Primary Outcome Measures

    Change from baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)

    Secondary Outcome Measures

    Change from baseline in MSDBP
    Change from baseline Mean Seated Systolic Blood Pressure (MSSBP)
    Blood pressure responder rate
    Rate of patients who achieved target blood pressure (MSSBP < 140 mmHg and MSDBP < 90 mmHg), or MSSBP decrease > 20 mmHg from baseline or MSDBP decrease > 10 mmHg from baseline.

    Full Information

    First Posted
    April 7, 2013
    Last Updated
    April 9, 2013
    Sponsor
    Hanmi Pharmaceutical Company Limited
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01828359
    Brief Title
    The Efficacy and Safety Study of Anti-hypertension Combination Drug in Patients Uncontrolled With Monotherapy.
    Official Title
    An Eight-week, Randomized, Double-blind Multicenter Study to Compare the Efficacy and Safety of Amosartan® Tab 5/100mg Versus Cozaar® Plus Pro Tab in Patients With Essential Hypertension Uncontrolled With Losartan 100mg Monotherapy
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2013
    Overall Recruitment Status
    Completed
    Study Start Date
    August 2010 (undefined)
    Primary Completion Date
    January 2013 (Actual)
    Study Completion Date
    January 2013 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Hanmi Pharmaceutical Company Limited

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The purpose of this study is to evaluate the blood pressure lowering effects of an amlodipine/losartan combination treatment and losartan/Hydrochlorothiazide combination treatment in patients with essential hypertension uncontrolled with losartan 100mg monotherapy.
    Detailed Description
    Quality assurance plan was implemented by site monitoring, including data validation and registry procedures and Source data verification to assess the accuracy, completeness by comparing the data to external data sources (medical records and paper case report forms). Data dictionary contains the registry, including the source of the variable, coding information (MedDRA ver12.0), and normal ranges. Statistical analysis were performed using SAS® Version 9.2, SAS institute, Cary, NC, USA

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hypertension

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    199 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Amosartan® tab
    Arm Type
    Experimental
    Arm Description
    Amlodipine 5mg /Losartan 100mg
    Arm Title
    Cozaar® plus pro tab
    Arm Type
    Active Comparator
    Arm Description
    Losartan 100mg/ HCTZ 12.5mg
    Intervention Type
    Drug
    Intervention Name(s)
    Amosartan® tab
    Other Intervention Name(s)
    Amlodipine 5mg /Losartan 100mg
    Intervention Description
    comparison of different combination of anti-hypertension drug
    Intervention Type
    Drug
    Intervention Name(s)
    Cozaar® plus pro tab
    Other Intervention Name(s)
    Losartan 100mg/ HCTZ 12.5mg
    Intervention Description
    comparison of different combination of anti-hypertension drug
    Primary Outcome Measure Information:
    Title
    Change from baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)
    Time Frame
    Baseline, Week 8
    Secondary Outcome Measure Information:
    Title
    Change from baseline in MSDBP
    Time Frame
    Baseline, week 4
    Title
    Change from baseline Mean Seated Systolic Blood Pressure (MSSBP)
    Time Frame
    Baseline, Week 4 and 8
    Title
    Blood pressure responder rate
    Description
    Rate of patients who achieved target blood pressure (MSSBP < 140 mmHg and MSDBP < 90 mmHg), or MSSBP decrease > 20 mmHg from baseline or MSDBP decrease > 10 mmHg from baseline.
    Time Frame
    Baseline, Week 4 and 8

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    20 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: 20 aged or over Patients with blood pressure measured at Visit 1; 90mmHg≤MSDBP mmHg if on anti-hypertensive drugs, 95mmHg≤MSDBP mmHg if not on anti-hypertensive drugs Patients with blood pressure measured at Visit 2 were 90mmHg≤MSDBP mmHg (non-responder to Losartan 100mg for 4-week treatment) Exclusion Criteria: Patients with too high Blood pressure •≥ sitSBP 20mmHg or ≥ sitDBP 10mmHg of variation in three measurements from the reference arm selected at Screening History of hypersensitivity to CCB ,Angiotensin II receptor blockers or Sulfonamide. Secondary hypertension or suspected to be
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Taehoon Ahn, Ph.D.
    Organizational Affiliation
    Gachon University Gil Medical Center
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    The Efficacy and Safety Study of Anti-hypertension Combination Drug in Patients Uncontrolled With Monotherapy.

    We'll reach out to this number within 24 hrs